Perceived relapse risk and desire for medication assisted treatment among persons seeking inpatient opiate detoxification

Journal of Substance Abuse Treatment

Volumn 45, Issue 3, 2013, Pages 302-305

  Bailey, Genie L ^a,b   Herman, Debra S ^a,c   Stein, Michael D ^a,c  

^a BROWN UNIVERSITY   (United States)

^b Stanley Street Treatment and Resources Inc ^*  (United States)

^c BUTLER HOSPITAL   (United States)

Author keywords

Aftercare; Detoxification; Medication; Opiates; Relapse

Indexed keywords

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CAUCASIAN; DETOXIFICATION; ETHNICITY; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PRIORITY JOURNAL; RELAPSE; RISK ASSESSMENT;

AFTERCARE; DETOXIFICATION; MEDICATION; OPIATES; RELAPSE;

ADULT; FEMALE; HUMANS; INPATIENTS; MALE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT DISCHARGE; PATIENT PREFERENCE; RECURRENCE; RISK; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS; YOUNG ADULT;

EID: 84880345113     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2013.04.002     Document Type: Article

References (37)

1. Amato L., Davoli M., Ferri M., Ali R. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database of Systematic Reviews 2004, CD003409.
2. Amato L., Davoli M., Ferri M., Gowing L., Perucci C.A. Effectiveness of interventions on opiate withdrawal treatment: An overview of systematic reviews. Drug and Alcohol Dependence 2004, 73:219-226.
3. Amato L., Minozzi S., Davoli M., Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database of Systematic Reviews 2011, CD004147.
4. Azur M.J., Stuart E.A., Frangakis C., Leaf P.J. Multiple imputation by chained equations: What is it and how does it work?. International Journal of Methods in Psychiatric Research 2011, 20:40-49.
5. Battersby M., Von Korff M., Schaefer J., Davis C., Ludman E., Greene S.M., et al. Twelve evidence-based principles for implementing self-management support in primary care. Joint Commission Journal on Quality and Patient Safety 2010, 36:561-570.
6. Broers B., Giner F., Dumont P., Mino A. Inpatient opiate detoxification in Geneva: Follow-up at 1 and 6months. Drug and Alcohol Dependence 2000, 58:85-92.
7. Campbell B.K., Tillotson C.J., Choi D., Bryant K., DiCenzo J., Provost S.E., et al. Predicting outpatient treatment entry following detoxification for injection drug use: The impact of patient and program factors. Journal of Substance Abuse Treatment 2010, 38(Suppl. 1):S87-S96.
8. Carrier E., McNeely J., Lobach I., Tay S., Gourevitch M.N., Raven M.C. Factors associated with frequent utilization of crisis substance use detoxification services. Journal of Addictive Diseases 2011, 30:116-122.
9. Coleman K., Austin B.T., Brach C., Wagner E.H. Evidence on the Chronic Care Model in the new millennium. Health Affairs (Millwood) 2009, 28:75-85.
10. Cunningham C.O., Giovanniello A., Li X., Kunins H.V., Roose R.J., Sohler N.L. A comparison of buprenorphine induction strategies: Patient-centered home-based inductions versus standard-of-care office-based inductions. Journal of Substance Abuse Treatment 2011, 40:349-356.
11. Fiellin D.A. The first three years of buprenorphine in the United States: Experience to date and future directions. Journal of Addiction Medicine 2007, 1:62-67.
12. Fiellin D.A., Moore B.A., Sullivan L.E., Becker W.C., Pantalon M.V., Chawarski M.C., et al. Long-term treatment with buprenorphine/naloxone in primary care: Results at 2-5years. The American Journal on Addictions 2008, 17:116-120.
13. Fischer J., Jenkins N., Bloor M., Neale J., Berney L. Drug users involvement in treatment decisions Accessed 1/7/13. http://www.jrf.org.uk/sites/files/jrf/2012-drug-user-treatment.pdf.
14. Fudala P., Bridge T., Herbert S., Williford W., Chiang C., Jones K., et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. The New England Journal of Medicine 2003, 349:949-958.
15. Gastfriend D.R. Intramuscular extended-release naltrexone: Current evidence. Annals of the New York Academy of Sciences 2011, 1216:144-166.
16. Gossop M., Green L., Phillips G., Bradley B. Lapse, relapse and survival among opiate addicts after treatment. A prospective follow-up study. The British Journal of Psychiatry 1989, 154:348-353.
17. Gossop M., Stewart D., Browne N., Marsden J. Factors associated with abstinence, lapse or relapse to heroin use after residential treatment: protective effect of coping responses. Addiction 2002, 97:1259-1267.
18. Institute of Medicine Treating drug problems (Vol. 1) 1990, National Academy Press, Washington DC. D.R. Gerstein, H.J. Harwood (Eds.).
19. Kreek M.J., Borg L., Ducat E., Ray B. Pharmacotherapy in the treatment of addiction: Methadone. Journal of Addictive Diseases 2010, 29:200-216.
20. Krupitsky E., Nunes E.V., Ling W., Illeperuma A., Gastfriend D.R., Silverman B.L. Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomised trial. The Lancet 2011, 377:1506-1513.
21. Lee S.Y., Morrissey J.P., Thomas K.C., Carter W.C., Ellis A.R. Assessing the service linkages of substance abuse agencies with mental health and primary care organizations. The American Journal of Drug and Alcohol Abuse 2006, 32:69-86.
22. Luty J. Treatment preferences of opiate-dependent patients. Psychiatric Bulletin 2004, 28:47-50.
23. Mark T.L., Dilonardo J.D., Chalk M., Coffey R. Factors associated with the receipt of treatment following detoxification. Journal of Substance Abuse Treatment 2003, 24:299-304.
24. Mark T.L., Dilonardo J.D., Chalk M., Coffey R.M. Trends in inpatient detoxification services, 1992-1997. Journal of Substance Abuse Treatment 2002, 23:253-260.
25. Mattick R.P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews 2009, CD002209.
26. Mattick R.P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews 2008, CD002207.
27. Mayet S., Farrell M., Ferri M., Amato L., Davoli M. Psychosocial treatment for opiate abuse and dependence. Cochrane Database of Systematic Reviews 2005, CD004330.
28. Ridge G., Gossop M., Lintzeris N., Witton J., Strang J. Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. Journal of Substance Abuse Treatment 2009, 37:95-100.
29. Royston P. Multiple imputation of missing values: Update. The Stata Journal 2005, 5:188-201.
30. Royston P. Multiple imputation of missing values: Update of ice. The Stata Journal 2005, 5:527-536.
31. Royston P. Multiple imputation of missing values: further update of ice, with an emphasis on interval censoring. The Stata Journal 2007, 7:445-464.
32. Smyth B.P., Barry J., Keenan E., Ducray K. Lapse and relapse following inpatient treatment of opiate dependence. Irish Medical Journal 2010, 103:176-179.
33. Sohler N.L., Li X., Kunins H.V., Sacajiu G., Giovanniello A., Whitley S., et al. Home- versus office-based buprenorphine inductions for opioid-dependent patients. Journal of Substance Abuse Treatment 2010, 38:153-159.
34. StataCorp Stata Statistical Software: Release 10.1 2008, StataCorp LP, College Station, TX.
35. Substance Abuse and Mental Health Services Administration The DASIS report: Admissions for detoxification, 2001 2004, Rockville, MD.
36. U.S. Department of Health and Human Services. (1995). Detoxification From Alcohol and Other Drugs: Treatment Improvement Protocol (TIP) Series 19. (DHHS Publication No. (SMA) 95-3046). Rockville, MD:.
37. Watkins K., Pincus H.A., Tanielian T.L., Lloyd J. Using the chronic care model to improve treatment of alcohol use disorders in primary care settings. Journal of Studies on Alcohol 2003, 64:209-218.